Dermavant’s senior leadership team includes some of the most accomplished specialty biopharmaceutical executives in medical dermatology. Members of this team have a track record of developing and commercializing innovative products that are among the best-known prescription dermatology brands. They possess rich industry knowledge, a passion for science, and a shared commitment to improving patients’ lives.
Prior to joining Dermavant in July 2017, Dr. Fouse served as President and Chief Operating Officer of Celgene Corporation, and as a member of their Board of Directors through June 2017. She joined Celgene in 2010 as Chief Financial Officer and was named president of the company’s global Hematology & Oncology franchise in 2014. Her experience at Celgene included working closely with the business unit that launched OTEZLA for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis.
Before joining Celgene, Dr. Fouse served as Chief Financial Officer of Bunge Limited, a leading global agribusiness and food company. She has also served as Senior Vice President, Chief Financial Officer and Head of Corporate Strategy at Alcon Laboratories, a leading ophthalmic pharmaceutical and medical device company. Prior to her time with Alcon she held a variety of senior leadership roles with international companies and spent almost a decade of her career in Switzerland. Dr. Fouse earned her BA and an MA in Economics and a PhD in Finance from the University of Texas at Arlington.
Vince Ippolito has over thirty years of experience in the pharmaceutical industry, including twenty years in dermatology. Prior to joining Dermavant in September 2017, Mr. Ippolito served as the Chief Operating Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-focused biopharmaceutical company. At Anacor, Mr. Ippolito was responsible for building marketing and sales functions, as well as developing the company’s product portfolio. Prior to Anacor, he was Executive Vice President at Medicis Pharmaceutical Corporation, an industry-leading dermatology company.
Over the course of his career, Mr. Ippolito has launched more than twenty brands in dermatology and he has played a leading role in two of the largest dermatology acquisitions of the past five years with combined valuations of $7.8 billion. Mr. Ippolito holds a BA in Business Administration, Management, and Operations from the University of Wisconsin with a minor in East Asian Studies from Sophia University in Japan.
As Chief Financial Officer, Ric Peterson brings over 20 years of successful global financial leadership to Dermavant. He has an outstanding record of developing corporate business and finance strategy, business development to achieve corporate strategic objectives and creating value for pharma and biotech businesses. Mr. Peterson joined Dermavant in March 2018. He has extensive experience in the dermatology space, previously serving as Chief Financial Officer at Sienna Biopharmaceuticals and Novan Therapeutics, two clinical-stage biopharmaceutical companies developing treatments for the field of dermatology.
Prior to that time, Mr. Peterson served as Chief Financial Officer, Executive Vice President and Treasurer of Medicis Pharmaceutical Corporation through the company’s $2.6 billion acquisition in 2012. As Chief Financial Officer of Medicis, he was responsible for financial and business operations, business development and information technology. He received his BS in Accounting from Arizona State University.
Jim Lee brings over 19 years of experience in successfully developing a number of dermatologic products across various indications in the field of dermatology. His contributions and innovations have distinguished Dr. Lee as a leader in dermatology development. Among other treatments, he was instrumental in developing the prescription dermatology medications, ALDARA and STELARA. Dr. Lee joined Dermavant in August 2016 and has been instrumental in the rapid development of a robust dermatology pipeline. Previously, he served as head of the dermatology clinical development group at GSK since 2011.
Dr. Lee has held positions of increasing responsibility in clinical development and medical affairs at Stiefel/GSK, Graceway Pharmaceuticals, Johnson and Johnson, and 3M Pharmaceuticals. Dr. Lee earned a BA in biochemistry from Carleton College, in Northfield, Minnesota and graduated from the Medical Scholars Program at the University of Illinois, receiving a PhD in biochemistry and an MD from the College of Medicine.
Following a distinguished career in academia and years of experience in the pharmaceutical industry, Dr. Rubenstein joined Dermavant in March 2018 from GlaxoSmithKline Dermatology. At GSK, he built an industry-leading dermatology drug development organization as VP, Discovery and Preclinical Development.
Prior to GSK, Dr. Rubenstein held academic roles at the University of North Carolina at Chapel Hill, most recently serving as the Louis C. Skinner Jr. Distinguished Professor of Dermatology.
Dr. Rubenstein received his A.B. in Molecular Biology from Princeton University and his M.D. and Ph.D. from Duke University School of Medicine. He completed his dermatology residency and postdoctoral fellowship in dermatology and biology at UNC-Chapel Hill.
Chris Van Tuyl is a distinguished business lawyer with extensive experience in multiple corporate and transactional matters. His expertise includes mergers and acquisitions, debt and equity securities offerings, venture capital transactions, SEC reporting, corporate governance, commercial contracting and compliance programs. With more than 18 years of experience, Mr. Van Tuyl has served as legal counsel for clients in a wide range of industries, including pharmaceuticals and healthcare.
Mr. Van Tuyl joined Dermavant in March 2018 from Sacks Tierney P.A., where he was a partner in the firm’s corporate practice group. He previously served as Legal Executive at FIS Global, where he managed strategic acquisitions, as well as securities, governance and organizational matters. Prior to joining FIS, Mr. Van Tuyl served as Corporate Secretary, Chief Compliance Officer, and Associate General Counsel at Rayonier, Inc., where he oversaw key aspects of the company’s multi-billion-dollar spinoff of its chemicals business in 2014. Prior to joining Rayonier, Mr. Van Tuyl served as Associate General Counsel at Medicis Pharmaceutical Corporation through the company’s $2.6 billion acquisition in 2012. From 2000 to 2009, Mr. Van Tuyl was a corporate attorney at Squire Sanders & Dempsey LLP in Phoenix and Clifford Chance LLP in New York. He received his BS in Finance summa cum laude from Arizona State University and his JD from Duke University School of Law.
Ariel Jasie is an experienced business leader with a demonstrated history of success in the biotechnology industry. He is highly skilled in all phases and multiple forms of partnering, transactions, collaborations, capital raises, company building, management, and strategy. Mr. Jasie joined Dermavant in March 2018 from Codiak BioSciences, a leader in exosome therapeutics, where he was Chief Business Officer. Prior to that, Mr. Jasie served in various roles at Celgene Corporation, most recently as Executive Director for Strategy and Operations for the company’s Research & Early Development Group.
Mr. Jasie previously served on the Celgene business development team, leading numerous deals including M&A, in-licensing, collaborations, strategic equity investments, seeding, syndicating and constructing “build to buys,” and serving as board observer to certain collaboration partners and equity investments. Mr. Jasie initially joined Celgene as Corporate Counsel, focusing on transactional work and supporting business development, technical operations, research, and clinical operations. Before joining Celgene, Mr. Jasie served as in-house counsel at Reliant Pharmaceuticals through the company’s $1.6 billion acquisition in 2007. He received his BA in History from the University of Maryland and his JD from Brooklyn Law School.
Howie McKibbon joined Dermavant in October 2017 as Senior Vice President, Commercial Operations responsible for all commercial activity. He previously served as Senior Vice President, Sales and Marketing at Anacor Pharmaceuticals, a dermatology-focused biopharmaceutical company where he built the Sales, Marketing, Managed Markets, Market Access and Trade functions. Prior to Anacor, he was the Vice President, Dermatology, Immunology and Podiatry at Medicis Pharmaceuticals a dermatology-focused company.
Over the course of his career Mr. McKibbon has launched 15 products including 11 in dermatology. He has managed over 30 dermatology products and played a significant role in two of the largest dermatology acquisitions with combined valuations of $7.8 billion. His background also includes sales and marketing leadership positions across portfolios of neuroscience, oncology and pain brands from launch to exclusivity at Cephalon and Wyeth Pharmaceuticals. He holds a B.A. in History from the University of South Florida, an MBA from Mercer University’s Stetson School of Business and Economics and a Doctor of Pharmacy from Mercer University’s Southern School of Pharmacy.
In her extensive clinical career, Dr. Rosanne Fidelus-Gort has established herself as an outstanding educator, researcher, author, and corporate leader in many aspects of biology, medicine, and pharmaceutical science. Prior to joining Dermavant in April 2018, Dr. Fidelus-Gort served as Executive Director and Global Clinical Lead for the Dermatology division of Pfizer, where she supported and designed multiple clinical trials in psoriasis, atopic dermatitis, alopecia areata and vitiligo and due diligence studies in dermatology, including the acquisition of Anacor. Before that, Dr. Fidelus-Gort was executive director and clinical project lead for Teva Pharmaceuticals, Incyte Corporation, and Centocor.
Throughout her career, Dr. Fidelus-Gort has excelled as a leader in clinical study design and research and the successful development of numerous pharmaceutical treatments. She has also collaborated extensively with recognized scientific thought leaders in dermatology to validate new clinical study designs. The co-author of 20 research studies and faculty at several prominent universities, she is a recognized leader in her field. Dr. Fidelus-Gort earned her Bachelor of Science from College of St. Francis and her PhD in Clinical Immunology from Rush University.
Anna Tallman combines 20 years of leadership in Medical Affairs with in-depth clinical experience in multiple therapeutic areas including dermatology, infectious disease, central nervous system, and pain. Dr. Tallman is a proven leader in building Medical Affairs infrastructure while also creating and driving medical strategy aligned with commercial strategy and supporting corporate objectives. She is widely recognized for exceptional relationship development skills and ability to implement valuable collaborative projects with internal colleagues, co-development partners, key opinion leaders, and advocacy groups.
Prior to joining the Dermavant team in March 2018, Dr. Tallman served as Global Therapeutic Area Team Leader, Dermatology with Pfizer where she was instrumental in the acquisition and integration of Anacor Pharmaceuticals and the subsequent launch of EUCRISA. Previously, she was Medical Director for a variety of pharmaceutical companies where she successfully launched many products. These include Optimer Pharmaceuticals (DIFICID), Strativa Pharmaceuticals (ZUPLENZ & ORAVIG), Elan Pharmaceuticals (TYSABRI), and Pfizer (RELPAX). Dr. Tallman earned her Doctor of Pharmacy degree from University of Michigan and completed a residency at University of Illinois at Chicago.
John Sall brings to Dermavant a broad drug development background with experience from academia, large pharma, biotech, and a healthcare consultancy organization. He is a proven leader with over 15 years of Global Regulatory Affairs experience managing teams focused on worldwide approval of novel medicines in therapeutic areas including dermatology, infectious disease, neurology, respiratory, and pain management.
Prior to joining Dermavant, Sall was the Vice President of Global Regulatory Affairs for Roivant Sciences where, for the past two years, he built and led a team supporting a diverse portfolio of up to 15 assets in various therapeutic areas. Prior to this position, he was the Global Director and Care Area Lead of Regulatory Affairs at Stiefel, a GSK company, managing the psoriasis and atopic dermatitis development portfolio. He has held various leadership positions in Global Regulatory Affairs at AbbVie, Hospira, Cephalon and Novartis. Sall received his BS in Analytical Chemistry from University of Michigan, PhD in Pharmacology from Wayne State University, and PharmD from Nova Southeastern University.
Paul Seaback brings nearly 25 years of commercial and clinical pharmaceutical supply chain and manufacturing experience to his role as SVP, Manufacturing and Supply Chain. Early in his career he held positions in active pharmaceutical ingredient and drug product manufacturing sites before assuming roles developing and leading global supply chains. Prior to joining Dermavant in May 2018, Mr. Seaback was VP, Supply Chain and Sourcing Operations at Ignyta until its acquisition by Roche. Mr. Seaback has also led the global supply chain and manufacturing at Gilead Sciences and Medicis Pharmaceutical and held positions of increasing responsibilities with Hospira, Mayne Pharma, and Novartis.
Over the course of his career, Mr. Seaback has led the supply chain for several new product introductions across multiple therapeutic areas and regions, including SOVALDI, HARVONI and GENVOYA. He has implemented many strategic initiatives enabling integration and continuous improvement across the global supply chain. Mr. Seaback earned his B.S. in Business Administration, Economics and Marketing from Colorado State University – Pueblo. He is on the advisory boards for Bio Supply Management Alliance and Metropolitan State University of Denver, School of Business.